Clinical Trials, Phase II as Topic

"Clinical Trials, Phase II as Topic" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Works about studies that are usually controlled to assess the effectiveness and dosage (if appropriate) of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques. These studies are performed on several hundred volunteers, including a limited number of patients with the target disease or disorder, and last about two years. This concept includes phase II studies conducted in both the U.S. and in other countries.

Descriptor ID	D017322
MeSH Number(s)	E05.318.760.250.500.210 N05.715.360.775.088.500.210 N06.850.520.450.250.250.210
Concept/Terms	Clinical Trials, Phase II as Topic Clinical Trials, Phase II as Topic Evaluation Studies, FDA Phase II as Topic Evaluation Studies, FDA Phase II as Topic Evaluation Studies, FDA Phase 2 as Topic Drug Evaluation, FDA Phase II as Topic Drug Evaluation, FDA Phase II as Topic Drug Evaluation, FDA Phase 2 as Topic

Below are MeSH descriptors whose meaning is more general than "Clinical Trials, Phase II as Topic".

Analytical, Diagnostic and Therapeutic Techniques and Equipment [E]
Investigative Techniques [E05]
Epidemiologic Methods [E05.318]
Epidemiologic Study Characteristics [E05.318.760]
Clinical Studies as Topic [E05.318.760.250]
Clinical Trials as Topic [E05.318.760.250.500]
Clinical Trials, Phase II as Topic [E05.318.760.250.500.210]
Health Care [N]
Health Care Quality, Access, and Evaluation [N05]
Quality of Health Care [N05.715]
Health Care Evaluation Mechanisms [N05.715.360]
Epidemiologic Study Characteristics [N05.715.360.775]
Clinical Studies as Topic [N05.715.360.775.088]
Clinical Trials as Topic [N05.715.360.775.088.500]
Clinical Trials, Phase II as Topic [N05.715.360.775.088.500.210]
Environment and Public Health [N06]
Public Health [N06.850]
Epidemiologic Methods [N06.850.520]
Epidemiologic Study Characteristics [N06.850.520.450]
Clinical Studies as Topic [N06.850.520.450.250]
Clinical Trials as Topic [N06.850.520.450.250.250]
Clinical Trials, Phase II as Topic [N06.850.520.450.250.250.210]

Below are MeSH descriptors whose meaning is related to "Clinical Trials, Phase II as Topic".

Below are MeSH descriptors whose meaning is more specific than "Clinical Trials, Phase II as Topic".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Clinical Trials, Phase II as Topic" by people in this website by year, and whether "Clinical Trials, Phase II as Topic" was a major or minor topic of these publications.

Bar chart showing 22 publications over 16 distinct years, with a maximum of 2 publications in 2011 and 2012 and 2013 and 2019 and 2021 and 2023

To see the data from this visualization as text, click here.

Year	Minor Topic	Total
2000	1	1
2003	1	1
2005	1	1
2009	1	1
2010	1	1
2011	2	2
2012	2	2
2013	2	2
2015	1	1
2017	1	1
2018	1	1
2019	2	2
2020	1	1
2021	2	2
2022	1	1
2023	2	2

Below are the most recent publications written about "Clinical Trials, Phase II as Topic" by people in Profiles.

Mazer CD, Siadati-Fini N, Boehm J, Wirth F, Myjavec A, Brown CD, Koyner JL, Boening A, Engelman DT, Larsson TE, Renfurm R, de Varennes B, Noiseux N, Thielmann M, Lamy A, Laflamme M, von Groote T, Ronco C, Zarbock A. Study protocol of a phase 2, randomised, placebo-controlled, double-blind, adaptive, parallel group clinical study to evaluate the efficacy and safety of recombinant alpha-1-microglobulin in subjects at high risk for acute kidney injury following open-chest cardiac surgery (AKITA trial). BMJ Open. 2023 04 06; 13(4):e068363.

View in: PubMed
Paul B, Liedtke M, Khouri J, Rifkin R, Gandhi MD, Kin A, Levy MY, Silbermann R, Cottini F, Sborov DW, Sandhu I, Villarreal L, Murphy M, Gu L, Chen A, Rajakumaraswamy N, Usmani SZ. A phase II multi-arm study of magrolimab combinations in patients with relapsed/refractory multiple myeloma. Future Oncol. 2023 Jan; 19(1):7-17.

View in: PubMed
Sklavenitis-Pistofidis R, Aranha MP, Redd RA, Baginska J, Haradhvala NJ, Hallisey M, Dutta AK, Savell A, Varmeh S, Heilpern-Mallory D, Ujwary S, Zavidij O, Aguet F, Su NK, Lightbody ED, Bustoros M, Tahri S, Mouhieddine TH, Wu T, Flechon L, Anand S, Rosenblatt JM, Zonder J, Vredenburgh JJ, Boruchov A, Bhutani M, Usmani SZ, Matous J, Yee AJ, Jakubowiak A, Laubach J, Manier S, Nadeem O, Richardson P, Badros AZ, Mateos MV, Trippa L, Getz G, Ghobrial IM. Immune biomarkers of response to immunotherapy in patients with high-risk smoldering myeloma. Cancer Cell. 2022 11 14; 40(11):1358-1373.e8.

View in: PubMed
Georas SN, Wright RJ, Ivanova A, Israel E, LaVange LM, Akuthota P, Carr TF, Denlinger LC, Fajt ML, Kumar R, O'Neal WK, Phipatanakul W, Szefler SJ, Aronica MA, Bacharier LB, Burbank AJ, Castro M, Crotty Alexander L, Bamdad J, Cardet JC, Comhair SAA, Covar RA, DiMango EA, Erwin K, Erzurum SC, Fahy JV, Gaffin JM, Gaston B, Gerald LB, Hoffman EA, Holguin F, Jackson DJ, James J, Jarjour NN, Kenyon NJ, Khatri S, Kirwan JP, Kraft M, Krishnan JA, Liu AH, Liu MC, Marquis MA, Martinez F, Mey J, Moore WC, Moy JN, Ortega VE, Peden DB, Pennington E, Peters MC, Ross K, Sanchez M, Smith LJ, Sorkness RL, Wechsler ME, Wenzel SE, White SR, Zein J, Zeki AA, Noel P. The Precision Interventions for Severe and/or Exacerbation-Prone (PrecISE) Asthma Network: An overview of Network organization, procedures, and interventions. J Allergy Clin Immunol. 2022 02; 149(2):488-516.e9.

View in: PubMed
Costa LJ, Lin Y, Cornell RF, Martin T, Chhabra S, Usmani SZ, Jagannath S, Callander NS, Berdeja JG, Kang Y, Vij R, Godby KN, Malek E, Neppalli A, Liedtke M, Fiala M, Tian H, Valluri S, Marino J, Jackson CC, Banerjee A, Kansagra A, Schecter JM, Kumar S, Hari P. Comparison of Cilta-cel, an Anti-BCMA CAR-T Cell Therapy, Versus Conventional Treatment in Patients With Relapsed/Refractory Multiple Myeloma. Clin Lymphoma Myeloma Leuk. 2022 05; 22(5):326-335.

View in: PubMed
Rizzo A, Mollica V, Dall'Olio FG, Ricci AD, Maggio I, Marchetti A, Rosellini M, Santoni M, Ardizzoni A, Massari F. Quality of life assessment in renal cell carcinoma?Phase II and III clinical trials published between 2010 and 2020: a systematic review. Future Oncol. 2021 Jul; 17(20):2671-2681.

View in: PubMed
Gill RR, Barlow J, Jaklitsch MT, Schmidlin EJ, Hartigan PM, Bueno R. Image-guided video-assisted thoracoscopic resection (iVATS): Translation to clinical practice-real-world experience. J Surg Oncol. 2020 Jun; 121(8):1225-1232.

View in: PubMed
Sarivalasis A, Boudousqui? C, Balint K, Stevenson BJ, Gannon PO, Iancu EM, Rossier L, Martin Lluesma S, Mathevet P, Sempoux C, Coukos G, Dafni U, Harari A, Bassani-Sternberg M, Kandalaft LE. A Phase I/II trial comparing autologous dendritic cell vaccine pulsed either with personalized peptides (PEP-DC) or with tumor lysate (OC-DC) in patients with advanced high-grade ovarian serous carcinoma. J Transl Med. 2019 11 26; 17(1):391.

View in: PubMed
Norgren L, Weiss N, Nikol S, Hinchliffe RJ, Lantis JC, Patel MR, Reinecke H, Ofir R, Rosen Y, Peres D, Aberman Z. PLX-PAD Cell Treatment of Critical Limb Ischaemia: Rationale and Design of the PACE Trial. Eur J Vasc Endovasc Surg. 2019 04; 57(4):538-545.

View in: PubMed
Rana R, Huang T, Koukos G, Fletcher EK, Turner SE, Shearer A, Gurbel PA, Rade JJ, Kimmelstiel CD, Bliden KP, Covic L, Kuliopulos A. Noncanonical Matrix Metalloprotease 1-Protease-Activated Receptor 1 Signaling Drives Progression of Atherosclerosis. Arterioscler Thromb Vasc Biol. 2018 06; 38(6):1368-1380.

View in: PubMed

People

Explore

Similar Concepts

Top Journals